Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for ...

School reopenings after COVID-19 closures significantly improved children's mental health, reducing diagnoses of depression, ...

Shayla Bergmann, MD, explains that recombinant von Willebrand factor is both safe and highly effective in controlling ...

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in ...

ICHRAs may help employers and employees manage rising premiums and the loss of extended tax credits, according to expert ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...

Panelists discuss how noninvasive risk assessments enable early detection and targeted management of fibrosis in MASH ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, ...

In interviews with The American Journal of Managed Care®, Jennifer Graff, PharmD, of Innov8 Health Policy; Joey Mattingly, PharmD, MBA, PhD, of the University of Utah College of Pharmacy; and Brian ...

Ryan Haumschild, PharmD, MS, MBA, introduces the faculty and sets the agenda to explore disease background, novel therapies, and operational considerations in relapsed/refractory multiple myeloma.

Panelists discuss how multidisciplinary collaboration is essential for preventing progression and improving outcomes in MASH care.

Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.